These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1119 related articles for article (PubMed ID: 33084982)

  • 1. Association of 1-deoxy-sphingolipids with steatosis but not steatohepatitis nor fibrosis in non-alcoholic fatty liver disease.
    Weyler J; Verrijken A; Hornemann T; Vonghia L; Dirinck E; von Eckardstein A; Vanwolleghem T; Michielsen P; Peiffer F; Driessen A; Hubens G; Staels B; Francque S; Van Gaal L
    Acta Diabetol; 2021 Mar; 58(3):319-327. PubMed ID: 33084982
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management.
    McPherson S; Hardy T; Henderson E; Burt AD; Day CP; Anstee QM
    J Hepatol; 2015 May; 62(5):1148-55. PubMed ID: 25477264
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The triglyceride-glucose index is associated with the severity of hepatic steatosis and the presence of liver fibrosis in non-alcoholic fatty liver disease: a cross-sectional study in Chinese adults.
    Guo W; Lu J; Qin P; Li X; Zhu W; Wu J; Xu N; Zhang Q
    Lipids Health Dis; 2020 Oct; 19(1):218. PubMed ID: 33028338
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Non-alcoholic fatty liver disease and type 2 diabetes mellitus: issues of the liver fibrosis diagnostics].
    Anisonyan AV; Sandler YG; Khaimenova TY; Keyan VA; Saliev KG; Sbikina ES; Vinnitskaya EV
    Ter Arkh; 2020 Sep; 92(8):73-78. PubMed ID: 33346465
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pediatric non-alcoholic fatty liver disease: an increasing public health issue.
    Berardis S; Sokal E
    Eur J Pediatr; 2014 Feb; 173(2):131-9. PubMed ID: 24068459
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Non-alcoholic fatty liver disease - histological scoring systems: a large cohort single-center, evaluation study.
    Rastogi A; Shasthry SM; Agarwal A; Bihari C; Jain P; Jindal A; Sarin S
    APMIS; 2017 Nov; 125(11):962-973. PubMed ID: 29076589
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sarcopenia is associated with severe liver fibrosis in patients with non-alcoholic fatty liver disease.
    Petta S; Ciminnisi S; Di Marco V; Cabibi D; Cammà C; Licata A; Marchesini G; Craxì A
    Aliment Pharmacol Ther; 2017 Feb; 45(4):510-518. PubMed ID: 28028821
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Utility of the ELF Test for Detecting Steatohepatitis in Morbid Obese Patients with Suspicion of Nonalcoholic Fatty Liver Disease.
    López IC; Aroca FG; Bernal MDF; Mompeán JAL; Bernal ÁB; Martínez AMH; Barba EM; Velasco JAN; Paricio PP
    Obes Surg; 2017 Sep; 27(9):2347-2353. PubMed ID: 28229316
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical validation of the FLIP algorithm and the SAF score in patients with non-alcoholic fatty liver disease.
    Nascimbeni F; Bedossa P; Fedchuk L; Pais R; Charlotte F; Lebray P; Poynard T; Ratziu V;
    J Hepatol; 2020 May; 72(5):828-838. PubMed ID: 31862486
    [TBL] [Abstract][Full Text] [Related]  

  • 10. C-peptide is associated with NAFLD inflammatory and fibrotic progression in type 2 diabetes.
    Wang N; Wang Y; Zhang W; Chen Y; Chen X; Wang C; Li Q; Chen C; Jiang B; Lu Y
    Diabetes Metab Res Rev; 2020 Feb; 36(2):e3210. PubMed ID: 31351021
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The HAALT Non-invasive Scoring System for NAFLD in Obesity.
    Sheth H; Bagasrawala S; Shah M; Ansari R; Olithselvan A; Lakdawala M
    Obes Surg; 2019 Aug; 29(8):2562-2570. PubMed ID: 31016455
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Elevated plasma copeptin levels identify the presence and severity of non-alcoholic fatty liver disease in obesity.
    Barchetta I; Enhörning S; Cimini FA; Capoccia D; Chiappetta C; Di Cristofano C; Silecchia G; Leonetti F; Melander O; Cavallo MG
    BMC Med; 2019 Apr; 17(1):85. PubMed ID: 31035998
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Growing burden of nonalcoholic fatty liver disease in Turkey: A single-center experience.
    Yılmaz Y; Kanı HT; Demirtaş CÖ; Kaya E; Sapmaz AF; Qutranji L; Alkayyali T; Batun KD; Batman M; Toy B; Çiftaslan A
    Turk J Gastroenterol; 2019 Oct; 30(10):892-898. PubMed ID: 31258138
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence and Risk Factors of Significant Fibrosis in Patients With Nonalcoholic Fatty Liver Without Steatohepatitis.
    Pelusi S; Cespiati A; Rametta R; Pennisi G; Mannisto V; Rosso C; Baselli G; Dongiovanni P; Fracanzani AL; Badiali S; Maggioni M; Craxi A; Fargion S; Prati D; Nobili V; Bugianesi E; Romeo S; Pihlajamaki J; Petta S; Valenti L
    Clin Gastroenterol Hepatol; 2019 Oct; 17(11):2310-2319.e6. PubMed ID: 30708111
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sarcopenia is an independent risk factor for non-alcoholic steatohepatitis and significant fibrosis.
    Koo BK; Kim D; Joo SK; Kim JH; Chang MS; Kim BG; Lee KL; Kim W
    J Hepatol; 2017 Jan; 66(1):123-131. PubMed ID: 27599824
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oxidized low-density lipoprotein antibodies/high-density lipoprotein cholesterol ratio is linked to advanced non-alcoholic fatty liver disease lean patients.
    Ampuero J; Ranchal I; Gallego-Durán R; Pareja MJ; Del Campo JA; Pastor-Ramírez H; Rico MC; Picón R; Pastor L; García-Monzón C; Andrade R; Romero-Gómez M
    J Gastroenterol Hepatol; 2016 Sep; 31(9):1611-8. PubMed ID: 26946071
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ectodysplasin A Is Increased in Non-Alcoholic Fatty Liver Disease, But Is Not Associated With Type 2 Diabetes.
    Bayliss J; Ooi GJ; De Nardo W; Shah YJH; Montgomery MK; McLean C; Kemp W; Roberts SK; Brown WA; Burton PR; Watt MJ
    Front Endocrinol (Lausanne); 2021; 12():642432. PubMed ID: 33746906
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence and Predictors of Non-Alcoholic Fatty Liver Disease in Morbidly Obese South Indian Patients Undergoing Bariatric Surgery.
    Praveenraj P; Gomes RM; Kumar S; Karthikeyan P; Shankar A; Parthasarathi R; Senthilnathan P; Rajapandian S; Palanivelu C
    Obes Surg; 2015 Nov; 25(11):2078-87. PubMed ID: 25835982
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictive value of ALT levels for non-alcoholic steatohepatitis (NASH) and advanced fibrosis in non-alcoholic fatty liver disease (NAFLD).
    Verma S; Jensen D; Hart J; Mohanty SR
    Liver Int; 2013 Oct; 33(9):1398-405. PubMed ID: 23763360
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Limited value of plasma cytokeratin-18 as a biomarker for NASH and fibrosis in patients with non-alcoholic fatty liver disease.
    Cusi K; Chang Z; Harrison S; Lomonaco R; Bril F; Orsak B; Ortiz-Lopez C; Hecht J; Feldstein AE; Webb A; Louden C; Goros M; Tio F
    J Hepatol; 2014 Jan; 60(1):167-74. PubMed ID: 23973932
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 56.